Cargando…
0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial
We determined the efficacy and safety of 0.1% RGN-259 ophthalmic solution (containing the regenerative protein thymosin ß4) in promoting the healing of persistent epithelial defects in patients with Stages 2 and 3 neurotrophic keratopathy. Complete healing occurred after 4 weeks in 6 of the 10 RGN-2...
Autores principales: | Sosne, Gabriel, Kleinman, Hynda K., Springs, Clark, Gross, Robert Hollis, Sung, Jihye, Kang, Shinwook |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820614/ https://www.ncbi.nlm.nih.gov/pubmed/36613994 http://dx.doi.org/10.3390/ijms24010554 |
Ejemplares similares
-
RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
por: Kim, Chae Eun, et al.
Publicado: (2018) -
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model
por: Sosne, Gabriel, et al.
Publicado: (2015) -
Development of the neurotrophic keratopathy questionnaire: qualitative research
por: Murray, Lindsey T., et al.
Publicado: (2020) -
Neurotrophic keratopathy: current challenges and future prospects
por: NaPier, Erin, et al.
Publicado: (2022) -
Neurotrophic keratopathy: Clinical presentation and effects of cenegermin
por: Bu, Julia Bing, et al.
Publicado: (2022)